Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Seligman

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Bioinformatics (Oxford, England)|October 24, 2009
The gputools package enables GPU computing in RJoshua Buckner, Justin Wilson, Mark Seligman, et al.
Plos Computational Biology|May 1, 2007
Coping with viral diversity in HIV vaccine designDavid C Nickle, Morgane Rolland, Mark A Jensen, et al.
Seminars in Oncology|February 24, 2005
Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensificationSteven K Seung, John W Smith, John Molendyk, et al.
Human Gene Therapy|July 30, 2003
Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological resultsAnnemieke Dols, John W Smith, Sybren L Meijer, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Bioinformatics (Oxford, England)|October 24, 2009
The gputools package enables GPU computing in RJoshua Buckner, Justin Wilson, Mark Seligman, et al.
Plos Computational Biology|May 1, 2007
Coping with viral diversity in HIV vaccine designDavid C Nickle, Morgane Rolland, Mark A Jensen, et al.
Seminars in Oncology|February 24, 2005
Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensificationSteven K Seung, John W Smith, John Molendyk, et al.
Human Gene Therapy|July 30, 2003
Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological resultsAnnemieke Dols, John W Smith, Sybren L Meijer, et al.
Pageof 1